Scarica l'app Stockscreener
82.67
1.32%
-1.13
Precedente Chiudi:
$83.80
Aprire:
$84.8
Volume 24 ore:
1.03M
Capitalizzazione di mercato:
$15.72B
Reddito:
$2.47B
Utile/perdita netta:
$205.46M
Rapporto P/E:
107.55
EPS:
0.7687
Flusso di cassa netto:
$163.21M
1 W Prestazione:
+2.20%
1M Prestazione:
-4.71%
6M Prestazione:
+3.89%
1 anno Prestazione:
-11.64%
Intervallo 1D:
$82.51
$84.80
Portata 52W:
$76.02
$99.56
Biomarin Pharmaceutical Inc. Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc.
Settore
Industria
Telefono
415-506-6700
Indirizzo
770 Lindaro Street, San Rafael, CA
Biomarin Pharmaceutical Inc. Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc. Borsa (BMRN) Ultime notizie
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
The Motley Fool
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
Benzinga
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Zacks Investment Research
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Zacks Investment Research
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
Zacks Investment Research
Biomarin Pharmaceutical Inc. Azioni (BMRN) Dati Finanziari
Biomarin Pharmaceutical Inc. (BMRN) Reddito 2024
BMRN ha riportato un ricavo (TTM) di $2.47 miliardi per il trimestre terminato il 2024-03-31, un +13.74% salita anno su anno.
Biomarin Pharmaceutical Inc. (BMRN) Reddito netto 2024
BMRN l'utile netto (TTM) è stato di $205.46 milioni per il trimestre terminato il 2024-03-31, un +186.89% aumento anno su anno.
Biomarin Pharmaceutical Inc. (BMRN) Flusso di cassa 2024
BMRN ha registrato un flusso di cassa disponibile (TTM) di $163.21 milioni per il trimestre conclusosi con 2024-03-31, un +649.72% aumento anno su anno.
Biomarin Pharmaceutical Inc. (BMRN) Utile per azione 2024
L'utile per azione (TTM) di BMRN è stato pari a $1.07 per il trimestre terminato il 2024-03-31, un +182.55% crescita anno su anno.
Biomarin Pharmaceutical Inc. Azioni (BMRN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Apr 12 '24 |
Option Exercise |
63.10 |
20,000 |
1,262,000 |
494,994 |
| BIENAIME JEAN JACQUES | Director |
Apr 12 '24 |
Sale |
91.26 |
20,000 |
1,825,200 |
474,994 |
| BIENAIME JEAN JACQUES | Director |
Apr 11 '24 |
Option Exercise |
63.10 |
20,000 |
1,262,000 |
494,994 |
| BIENAIME JEAN JACQUES | Director |
Apr 11 '24 |
Sale |
90.99 |
20,000 |
1,819,800 |
474,994 |
| Burkhart Erin | GVP, Chief Accounting Officer |
Apr 10 '24 |
Sale |
90.00 |
2,286 |
205,740 |
16,156 |
| Davis George Eric | EVP, Chief Legal Officer |
Mar 28 '24 |
Sale |
88.34 |
24,602 |
2,173,341 |
55,856 |
| Slamon Dennis | Director |
Mar 18 '24 |
Option Exercise |
79.70 |
10,000 |
797,000 |
40,809 |
| BIENAIME JEAN JACQUES | Director |
Mar 06 '24 |
Sale |
86.71 |
1,000 |
86,713 |
560,203 |
| FUCHS HENRY J | President, Worldwide R&D |
Mar 05 '24 |
Sale |
85.18 |
35,341 |
3,010,396 |
212,117 |
| Ajer Jeffrey Robert | EVP, Chief Commercial Officer |
Mar 05 '24 |
Sale |
87.07 |
4,000 |
348,280 |
94,047 |
0.02%
6.91%
Capitalizzazione:
|
Volume (24 ore):